{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:07:12Z","timestamp":1789873632178,"version":"4.0.1"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,12,24]],"date-time":"2003-12-24T00:00:00Z","timestamp":1072224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:p><jats:bold>Summary:\u2003<\/jats:bold>  <jats:italic>Purpose:<\/jats:italic> To evaluate pregabalin (PGB), 150 mg\/day, and PGB, 600 mg\/day, as an add\u2010on treatment for patients with refractory partial seizures concurrently treated with one to three anticonvulsants (AEDs).<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> An international (13 countries), multicenter (45 centers), 12\u2010week, double\u2010blind, randomized study in which patients with partial seizures received placebo (n = 96); PGB, 150 mg\/day (n = 99); or PGB, 600 mg\/day (n = 92); given 3 times a day (t.i.d.). The primary efficacy criterion was reduction in seizure frequency during treatment as compared with baseline, as measured by RRatio, the symmetrical percentage change in seizure rates determined from daily seizure diaries. The RRatio between the 8\u2010week baseline (pretreatment phase) and the 12\u2010week treatment period were compared between each of the PGB groups and the placebo group by using an analysis of variance analysis of the intent\u2010to\u2010treat population.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> PGB, 150 mg\/day and 600 mg\/day, were both significantly more effective than placebo in reducing the RRatio [\u201311.5 (p = 0.0007) and \u201331.4 (p \u2264 0.0001), respectively, vs. 0.9]. These RRatio values correspond to seizure\u2010frequency reductions from baseline of \u20131.8, 20.6, and 47.8% for placebo, 150 mg\/day, and 600 mg\/day, respectively. PGB efficacy was significantly dose related (p \u2264 0.0001). Secondary efficacy variables corroborated the findings of the primary analysis. Significantly more patients were responders (\u226550% reduction in seizure frequency) in the PGB, 600 mg\/day (43.5%), group than in the placebo group (6.2%) (p \u2264 0.001). PGB was well tolerated. Dose\u2010related, treatment\u2010emergent adverse events (\u226510%), mostly mild or moderate in intensity, were somnolence, dizziness, ataxia, diplopia, and weight gain. The withdrawal rate due to adverse events was 10% of patients at 150 mg\/day and 18.5% of patients at 600 mg\/day, compared with 6.2% of patients receiving placebo.<\/jats:p><jats:p> <jats:italic>Conclusions:<\/jats:italic> PGB, 150 mg\/day and 600 mg\/day, is highly effective and well\u2010tolerated add\u2010on therapy in patients with partial seizures.<\/jats:p>","DOI":"10.1111\/j.0013-9580.2004.31203.x","type":"journal-article","created":{"date-parts":[[2003,12,24]],"date-time":"2003-12-24T14:53:24Z","timestamp":1072277604000},"page":"20-27","source":"Crossref","is-referenced-by-count":230,"title":["Pregabalin Add\u2010on Treatment: A Randomized, Double\u2010blind, Placebo\u2010controlled, Dose\u2013Response Study in Adults with Partial Seizures"],"prefix":"10.1111","volume":"45","author":[{"given":"Santiago","family":"Arroyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Anhut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd E.","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Pregabalin 1008\u2010011 International Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,12,24]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"828","article-title":"Pregabalin (Pfizer)","volume":"2","author":"Selak I","year":"2001","journal-title":"Curr Opin Invest Drugs"},{"key":"e_1_2_6_3_2","first-page":"901","volume-title":"Antiepileptic drugs","author":"Ben\u2010Menachem E","year":"2002"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055433.55136.55"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.3.533"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000068024.20285.65"},{"issue":"7","key":"e_1_2_6_7_2","first-page":"253","article-title":"Pregabalin add\u2010on trial: double\u2010blind, multicenter study in patients with partial epilepsy","volume":"41","author":"Beydoun AA","year":"2000","journal-title":"Epilepsia"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.10.5768"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00172-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)00769-2"},{"key":"e_1_2_6_11_2","first-page":"1086","article-title":"Stimulus\u2010dependent nodulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin","volume":"295","author":"Dooley DJ","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00316-5"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00173-8"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(02)00295-9"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00108-9"},{"issue":"8","key":"e_1_2_6_16_2","first-page":"35","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of CI\u20101008 (pregabalin) and gabapentin in rats with maximal electroshock","volume":"38","author":"Welty D","year":"1997","journal-title":"Epilepsia"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B"},{"issue":"8","key":"e_1_2_6_18_2","first-page":"35","article-title":"Profile of anticonvulsant activity of pregabalin in animal models","volume":"38","author":"Taylor CP","year":"1997","journal-title":"Epilepsia"},{"issue":"8","key":"e_1_2_6_19_2","first-page":"29","article-title":"Comparison of S\u2010(+)\u20103 isobutyl GABA (pregabalin) and gabapentin against kindled hippocampal seizures","volume":"38","author":"Williamson J","year":"1997","journal-title":"Epilepsia"},{"key":"e_1_2_6_20_2","unstructured":"Pfizer Inc. Data on file. Ann Arbor Michigan U.S.A ."},{"key":"e_1_2_6_21_2","unstructured":"KuglerAR GarofaloEA.Pregabalin adjunctive therapy in patients with partial seizures: presented at the Southern Clinical Neurological Meeting. Costa Rica 2001."},{"issue":"7","key":"e_1_2_6_22_2","first-page":"84","article-title":"Population pharmacokinetic (PK) analyses of pregabalin (PGB) in adult patients with refractory partial seizures","volume":"42","author":"Bockbrader HN","year":"2001","journal-title":"Epilepsia"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_6_24_2","volume-title":"Coding symbols for a thesaurus of adverse event reaction terms (COSTART)","author":"Department of Health and Human Services","year":"1996"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1989.10478843"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01364.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb05561.x"},{"key":"e_1_2_6_28_2","first-page":"491","volume-title":"Clin Pharmacol Thera","author":"Miller R","year":"2003"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0013-9580.2004.31203.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0013-9580.2004.31203.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T14:19:36Z","timestamp":1697120376000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0013-9580.2004.31203.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,24]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1111\/j.0013-9580.2004.31203.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0013-9580.2004.31203.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,24]]}}}